Alzheimer's and Dementia: Translational Research and Clinical Interventions

ESCI-ISI SCOPUS (2015-2025)

  2352-8737

 

  Mỹ

 

Cơ quản chủ quản:  WILEY , John Wiley & Sons Inc.

Lĩnh vực:
Psychiatry and Mental HealthNeurology (clinical)

Phân tích ảnh hưởng

Các bài báo tiêu biểu

Inflammation as a central mechanism in Alzheimer's disease
Tập 4 Số 1 - Trang 575-590 - 2018
Jefferson W. Kinney, Shane M. Bemiller, Andrew S. Murtishaw, Amanda M. Leisgang, Arnold Salazar, Bruce T. Lamb
AbstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD. The sustained activation of the brain's resident macrophages (micro... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2018
Tập 4 Số 1 - Trang 195-214 - 2018
Jeffrey L. Cummings, Garam Lee, Aaron Ritter, Kate Zhong
AbstractIntroductionTreatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov.MethodsClinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2017
Tập 3 Số 3 - Trang 367-384 - 2017
Jeffrey L. Cummings, Garam Lee, Travis Mortsdorf, Aaron Ritter, Kate Zhong
AbstractIntroductionThere is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies.MethodsWe assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed 1/5/2017.ResultsThere are 105 agents in the AD treatment development pipeline, of which 25 agents are... hiện toàn bộ
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health
Tập 3 Số 3 - Trang 291-300 - 2017
Michael J. Wheeler, Paddy C. Dempsey, Megan S. Grace, Kathryn A. Ellis, Paul A. Gardiner, Daniel J. Green, David W. Dunstan
AbstractCognitive decline leading to dementia represents a global health burden. In the absence of targeted pharmacotherapy, lifestyle approaches remain the best option for slowing the onset of dementia. However, older adults spend very little time doing moderate to vigorous exercise and spend a majority of time in sedentary behavior. Sedentary behavior has been linked to poor glycemic control and... hiện toàn bộ
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints
Tập 4 - Trang 444-449 - 2018
Rebecca E. Amariglio, Rachel F. Buckley, Elizabeth C. Mormino, Gad A. Marshall, Keith A. Johnson, Dorene M. Rentz, Reisa A. Sperling
AbstractIntroductionTo investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden.MethodsTwo hundred seventy‐nine clinically normal older participants (mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of community‐dwe... hiện toàn bộ
Accelerating drug development for Alzheimer's disease through the use of data standards
Tập 3 - Trang 273-283 - 2017
Jon Neville, Steve Kopko, Klaus Romero, Brian Corrigan, Bob Stafford, Elizabeth LeRoy, Steve Broadbent, Martin Cisneroz, Ethan Wilson, Eric Reiman, Hugo Vanderstichele, Stephen P. Arnerić, Diane Stephenson
AbstractIntroductionThe exceedingly high rate of failed trials in Alzheimer's disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. Data standards allow for proper integration of clinical data sets and represent the essential foundation for... hiện toàn bộ
No synergistic effect of subtherapeutic doses of donepezil and EVP‐6124 in healthy elderly subjects in a scopolamine challenge model
Tập 5 - Trang 89-98 - 2019
Anne Catrien Baakman, Ricardo Alvarez-Jimenez, Gordon Loewen, Marieke L. de Kam, Karen Broekhuizen, Dana C. Hilt, Geert Jan Groeneveld
AbstractIntroductionDonepezil is a widely used cholinesterase inhibitor in the management of Alzheimer's disease. Despite large‐scaled evidence for its efficacy, elevated peripheral ACh levels often lead to side effects and are dose limiting. The present exploratory study is designed to determine the potentiation of the effects of donepezil by cotreatment with EVP‐6124, an alpha‐7 nicotinic agonis... hiện toàn bộ
A single systemic inflammatory insult causes acute motor deficits and accelerates disease progression in a mouse model of human tauopathy
Tập 5 - Trang 579-591 - 2019
Megan Torvell, David W. Hampton, Peter Connick, Alasdair M.J. MacLullich, Colm Cunningham, Siddharthan Chandran
AbstractIntroductionNeuroinflammation, which contributes to neurodegeneration, is a consistent hallmark of dementia. Emerging evidence suggests that systemic inflammation also contributes to disease progression.MethodsThe ability of systemically administered lipopolysaccharide (LPS ‐ 500 μg/kg) to effect acute and chronic behavioural changes in C57BL/6 and P301S tauopathy mice was assessed. Marker... hiện toàn bộ
Estrogen activates Alzheimer's disease genes
Tập 5 - Trang 906-917 - 2019
Abhirami Ratnakumar, Samuel E. Zimmerman, Bryen A. Jordan, Jessica C. Mar
AbstractIntroductionWomen are at increased risk for Alzheimer's disease (AD), but the reason why remains unknown. One hypothesis is that low estrogen levels at menopause increases vulnerability to AD, but this remains unproven.MethodsWe compared neuronal genes upregulated by estrogen in ovariectomized female rhesus macaques with a database of >17,000 diverse gene sets and applied a rare variant bu... hiện toàn bộ
Randomized, controlled, proof‐of‐concept trial of MK‐7622 in Alzheimer's disease
Tập 4 - Trang 173-181 - 2018
Tiffini Voss, Jerry Li, Jeffrey Cummings, Martin Farlow, Christopher Assaid, Samar Froman, Heather Leibensperger, Linda Snow-Adami, Kerry Budd McMahon, Michael Egan, David Michelson
AbstractIntroductionWe evaluated the selective M1 muscarinic positive allosteric modulator, MK‐7622, as adjunctive cognitive enhancing therapy in individuals with Alzheimer's disease.MethodsA randomized, double‐blind, proof‐of‐concept trial was performed. Participants with mild‐to‐moderate Alzheimer's disease, being treated with an acetylcholinesterase inhibitor, were randomized 1:1 to 45 mg of MK... hiện toàn bộ